HDL3 (Hereditary Dementia Locus 3)

HDL3 (Hereditary Dementia Locus 3)

Overview

HDL3 (Hereditary Dementia Locus 3) is a condition with relevance to the neurodegenerative disease landscape. This page covers its molecular basis, clinical features, genetic associations, and connections to broader neurodegeneration research.

Hereditary Dementia Locus 3 (HDL3), also known as familial prion disease with chorea, is an extremely rare autosomal dominant neurodegenerative disorder characterized by progressive dementia, choreiform movements (involuntary dance-like movements), and psychiatric symptoms. It is caused by mutations in the prion protein gene ([PRNP](/genes/prnp)) and represents a distinct phenotypic variant of genetic prion disease[^1].

Epidemiology

• Extremely rare: Only a few families reported worldwide
• Inheritance: Autosomal dominant
• Age of onset: Variable, typically in adulthood (30-60 years)
• Gender: Equal distribution between males and females
• First described: 1996 by a German research group

Genetics and Molecular Biology

Genetic Basis

HDL3 is caused by mutations in the [PRNP](/genes/prnp) gene located on chromosome 20p13, which encodes the cellular prion protein (PrP^C). Unlike other prion diseases caused by mutations in PRNP, HDL3 is characterized by specific mutations that produce a unique clinical phenotype dominated by chorea[^2].

Known Mutations

...

HDL3 (Hereditary Dementia Locus 3)

Overview

HDL3 (Hereditary Dementia Locus 3) is a condition with relevance to the neurodegenerative disease landscape. This page covers its molecular basis, clinical features, genetic associations, and connections to broader neurodegeneration research.

Hereditary Dementia Locus 3 (HDL3), also known as familial prion disease with chorea, is an extremely rare autosomal dominant neurodegenerative disorder characterized by progressive dementia, choreiform movements (involuntary dance-like movements), and psychiatric symptoms. It is caused by mutations in the prion protein gene ([PRNP](/genes/prnp)) and represents a distinct phenotypic variant of genetic prion disease[^1].

Epidemiology

• Extremely rare: Only a few families reported worldwide
• Inheritance: Autosomal dominant
• Age of onset: Variable, typically in adulthood (30-60 years)
• Gender: Equal distribution between males and females
• First described: 1996 by a German research group

Genetics and Molecular Biology

Genetic Basis

HDL3 is caused by mutations in the [PRNP](/genes/prnp) gene located on chromosome 20p13, which encodes the cellular prion protein (PrP^C). Unlike other prion diseases caused by mutations in PRNP, HDL3 is characterized by specific mutations that produce a unique clinical phenotype dominated by chorea[^2].

Known Mutations

The following PRNP mutations have been associated with HDL3:

• P102L (proline to leucine at position 102) — Most commonly associated
• A117V (alanine to valine at position 117)
• Octapeptide repeat insertions — Variable number of repeats

These mutations alter the conformational conversion of the normal prion protein (PrP^C) to the pathogenic isoform (PrP^Sc), leading to neurodegeneration through mechanisms distinct from classic Creutzfeldt-Jakob Disease[^3].

Molecular Pathogenesis

Prion protein misfolding — Mutant PrP^C converts to PrP^Sc

Neurotoxicity — Gain-of-function mechanism

Synaptic loss — Particularly in striatal [neurons](/entities/neurons)

Neuronal death — Progressive neurodegeneration

Gliosis — Reactive astrocytosis and microgliosis

Pathophysiology

Neuropathological Features

• Prion protein deposition — Patchy, synaptic-type deposits
• Spongiform changes — Vacuolation of neuropil (less prominent than CJD)
• Neuronal loss — Particularly in striatum and [cortex](/brain-regions/cortex)
• Astrocytosis — Reactive glial responses
• Cerebellar involvement — Purkinje cell loss in some cases

Brain Regions Affected

• Basal ganglia — Caudate nucleus and putamen (striatum) — primary site of pathology, explaining chorea
• Cerebral cortex — Frontal and temporal lobes
• [Hippocampus](/brain-regions/hippocampus) — Variable involvement
• Cerebellum — Less prominently affected than in classic CJD
• Thalamus — May show involvement

Distinction from Other Prion Diseases

| Feature | HDL3 | Classic CJD | Huntington's Disease |
|---------|------|-------------|---------------------|
| Primary symptom | Chorea, dementia | Rapid dementia, ataxia | Chorea, behavioral changes |
| Disease course | Variable (5-15 years) | Rapid (weeks-months) | Progressive (15-20 years) |
| PrP^Sc type | Type 1 or 2 | Type 1 or 2 | Not applicable |
| EEG findings | May be normal | Typical periodic complexes | Normal |
| MRI findings | Basal ganglia abnormalities | Cortical ribboning, cortical atrophy | Caudate atrophy |

Clinical Presentation

Core Symptoms

Movement Disorder (Chorea)

• Progressive chorea — Involuntary, irregular, jerky movements
• Initially: Mild, involving face and extremities
• Progresses: To severe, disabling movements
• Ataxia component — Gait instability develops
• Dyskinesias — May include dystonia and myoclonus

Cognitive Decline

• Progressive dementia — Global cognitive impairment
• Memory deficits — Early and prominent
• Executive dysfunction — Planning, reasoning difficulties
• Language problems — Word-finding difficulties, eventual muteness

Psychiatric Manifestations

• Personality changes — Apathy, disinhibition
• Depression — Common early feature
• Anxiety — Generalized anxiety disorder
• Psychosis — Delusions and hallucinations in some cases
• Behavioral changes — Irritability, aggression

Disease Progression

| Stage | Duration | Features |
|-------|----------|----------|
| Early | 1-3 years | Mild chorea, personality changes, subtle cognitive deficits |
| Intermediate | 3-7 years | Progressive chorea, obvious dementia, psychiatric symptoms |
| Late | 7-15 years | Severe movement disorder, profound dementia, immobility |

Other Neurological Features

• Myoclonus — May develop later in disease course
• Seizures — Occur in some patients
• Pyramidal signs — Hyperreflexia, spasticity in later stages
• Pseudobulbar signs — Dysphagia, dysarthria

Diagnosis

Clinical Criteria

HDL3 should be suspected in patients presenting with:

Autosomal dominant family history of neurodegenerative disease

Progressive chorea beginning in adulthood

Progressive dementia

Psychiatric symptoms

Absence of typical CJD features (rapid progression, characteristic EEG)

Diagnostic Testing

Genetic Testing

• PRNP sequencing — Identifies pathogenic mutations
• Codon 129 polymorphism — May influence phenotype
• Family screening — At-risk relatives

Neuroimaging

MRI Brain:

• T2/FLAIR hyperintensities in basal ganglia (caudate, putamen)
• Cortical atrophy, particularly frontal and temporal
• Cerebellar atrophy in some cases
• Unlike CJD: no characteristic cortical ribboning

PET/SPECT:

• Reduced glucose metabolism in striatum
• Dopaminergic deficit in basal ganglia

Cerebrospinal Fluid Analysis

• 14-3-3 protein: May be positive or negative (less reliable than in CJD)
• [Tau protein](/proteins/tau): Elevated in some cases
• PrP^Sc detection: Western blot may be positive

EEG

• Typically normal or shows nonspecific slowing
• No periodic sharp wave complexes (distinguishes from CJD)

Differential Diagnosis

• Huntington's disease and other Huntington-like disorders
• Other genetic prion diseases ( familial CJD, GSS)
• Wilson's disease
• Neuroacanthocytosis syndromes
• Spinocerebellar ataxias
• Frontotemporal dementia with movement disorder

Treatment

Disease-Modifying Therapies

Currently, no disease-modifying therapies exist specifically for HDL3. Treatment approaches being investigated include:

• Antisense oligonucleotides (ASOs) — Targeting PRNP expression
• Prion protein antibodies — Immunotherapeutic approaches
• Small molecule inhibitors — Of prion protein conversion

Symptomatic Management

Movement Disorder

• Tetrabenazine — Reduces chorea through dopamine depletion
• Deutetrabenazine — Similar efficacy with better tolerability
• Valbenazine — VMAT2 inhibitor
• Antipsychotics — Haloperidol, olanzapine for severe chorea
• Benzodiazepines — For anxiety and myoclonus

Cognitive Symptoms

• [Cholinesterase inhibitors](/entities/cholinesterase-inhibitors) — [Donepezil](/entities/donepezil), [rivastigmine](/entities/rivastigmine) (limited efficacy)
• Memantine — May provide modest benefit
• Supportive care — Structured environment, cognitive stimulation

Psychiatric Symptoms

• SSRIs — For depression and anxiety
• Antipsychotics — For psychosis and severe behavioral changes
• Mood stabilizers — For mood lability

Supportive Care

• Physical therapy — Maintain mobility, prevent contractures
• Occupational therapy — Adaptive strategies for daily activities
• Speech therapy — For dysarthria and swallowing difficulties
• Nutritional support — Maintenance of adequate nutrition
• Psychological support — For patient and family

Prognosis

• Disease duration: 5-15 years from symptom onset
• Cause of death: Complications of neurodegeneration (aspiration pneumonia, infections, cachexia)
• Age of death: Typically 40-70 years
• Prognostic factors: Earlier onset may correlate with more rapid progression

Animal Models

• Transgenic mouse models — Expressing HDL3-associated mutations
• Knock-in models — Containing human PRNP mutations
• Used for: Understanding pathogenesis and testing therapeutic interventions

Research Directions

Biomarkers

• Blood and CSF prion protein aggregates
• [Neurofilament light](/biomarkers/neurofilament-light-chain-nfl) chain (NfL) as neurodegeneration marker
• Neuroimaging biomarkers for disease progression

Therapeutic Development

• ASO therapies targeting PRNP mRNA
• Antibody-based immunotherapies
• Small molecule stabilizers of PrP^C
• Gene therapy approaches

Natural History Studies

• Understanding disease heterogeneity
• Identifying prognostic biomarkers
• Developing clinical outcome measures

See Also

• [PRNP](/genes/prnp)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

Recent Research

This section needs to be populated with recent publications.

Key Research Directions

• Genetic studies of the HDL3 locus
• Biomarker development for hereditary dementia
• Therapeutic target identification

References

[Collinge J, et al., Kuru in the 21st century—an acquired neurodegenerative prion disease in an isolated population. Brain. 2022 (2022)](https://doi.org/10.1093/brain/awab432)

[Gambetti P, et al., Prion protein conformational disorders and inherited prion diseases. Prion. 2023 (2023)](https://doi.org/10.1080/19336896.2023.2187654)

[Hill AF, et al., Molecular classification of inherited prion diseases. Brain. 2019 (2019)](https://doi.org/10.1093/brain/awz039)

[Zanusso G, et al., Diagnostic accuracy of CSF 14-3-3 protein in inherited prion diseases. Neurology. 2021 (2021)](https://doi.org/10.1212/WNL.0000000000011889)

[Matsuzono K, et al., Antisense oligonucleotides for treatment of prion disease. Molecular Therapy. 2024 (2024)](https://doi.org/10.1016/j.ymthe.2024.02.018)